- Home
- AUUD vs XRTX Comparison
AUUD vs XRTX Comparison
Compare AUUD & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- XRTX
- Stock Information
- Founded
- AUUD 2012
- XRTX 2011
- Country
- AUUD United States
- XRTX Canada
- Employees
- AUUD N/A
- XRTX N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- XRTX Pharmaceuticals and Biotechnology
- Sector
- AUUD Technology
- XRTX Health Care
- Exchange
- AUUD Nasdaq
- XRTX Nasdaq
- Market Cap
- AUUD 2.9M
- XRTX 3.4M
- IPO Year
- AUUD 2021
- XRTX N/A
- Fundamental
- Price
- AUUD $3.98
- XRTX $0.96
- Analyst Decision
- AUUD
- XRTX
- Analyst Count
- AUUD 0
- XRTX 0
- Target Price
- AUUD N/A
- XRTX N/A
- AVG Volume (30 Days)
- AUUD 115.0K
- XRTX 224.7K
- Earning Date
- AUUD 08-06-2025
- XRTX 08-13-2025
- Dividend Yield
- AUUD N/A
- XRTX N/A
- EPS Growth
- AUUD N/A
- XRTX N/A
- EPS
- AUUD N/A
- XRTX N/A
- Revenue
- AUUD N/A
- XRTX N/A
- Revenue This Year
- AUUD N/A
- XRTX N/A
- Revenue Next Year
- AUUD N/A
- XRTX N/A
- P/E Ratio
- AUUD N/A
- XRTX N/A
- Revenue Growth
- AUUD N/A
- XRTX N/A
- 52 Week Low
- AUUD $2.88
- XRTX $0.80
- 52 Week High
- AUUD $31.62
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- AUUD 42.19
- XRTX 54.93
- Support Level
- AUUD $3.93
- XRTX $0.81
- Resistance Level
- AUUD $5.02
- XRTX $0.93
- Average True Range (ATR)
- AUUD 0.72
- XRTX 0.08
- MACD
- AUUD -0.12
- XRTX 0.01
- Stochastic Oscillator
- AUUD 1.49
- XRTX 68.20
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.